Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neeraj Agarwal, MD, FASCO TALAPRO-2 was a recent phase 3 study conducted in the first-line metastatic castration-resistant prostate cancer (mCRPC) setting. Patients were randomized to receive either enzalutamide plus talazoparib or enzalutamide plus placebo, and the researchers found that there was a 37 percent reduction in risk of progression or death among those who received enzalutamide plus talazoparib. Dive further into the findings and their implications for patients with mCRPC with Dr. Charles Turck and Dr. Neeraj Agarwal, Professor of Medicine at the Huntsman Cancer Institute at the University of Utah.

Host: Rishi Sekar, MD A recent study sought to investigate why there are disparities in mortality as well as access and participation in clinical trials among vulnerable prostate cancer populations. According to the findings, counties in the United States that had the highest prostate cancer mortality were less likely to have any clinical trials in the area. Dive further into the results with Dr. Rishi Sekar, who presented the “Disparities in Prostate Cancer Mortality and Clinical Trial Availability Across Vulnerable Populations” session at the 2024 ASCO Genitourinary Cancers Symposium.

Host: Zachery Reichert MD, PhD If hormonal therapies are not working for prostate cancer patients, chemotherapy may be a reliable alternative based on findings from a recent study. In fact, out of the 70 percent of patients who had pain when entering the study, 45 percent had their pain improved with chemotherapy. Dive more into the findings with Dr. Zachery Reichert, who presented the “Sequencing Hormonal Therapies After Treatment Intensification” session at the 2024 ASCO Genitourinary Cancers Symposium.

Host: Jacob Sands, MD Guest: Aakesh Desai, MD, MPH According to research featured at the 2023 ASCO Annual Meeting, novel immune checkpoint targets have the potential to inform drug development and combination strategies to optimize the care of patients with non-small cell lung cancer. Tune in to hear Dr. Jacob Sands explore the key findings with Dr. Aakash Desai, an Assistant Professor of Medicine at the O’Neal Cancer Center at the University of Alabama at Birmingham.

Guest: Jessica E. Hawley M.D. M.S. For patients who start out with hormone sensitive prostate cancer, there's a period of time where the prostate cancer cells are responsive to suppressing testosterone production. So there’s a nice disease response early in that time period after diagnosis and when initial treatment has begun, but how long is each patient going to respond to that initial treatment, and what role does the multidisciplinary team have? Dive in with Dr. Jessica Hawley, Medical Oncologist at Fred Hutch Cancer Center and an Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Tomasz Beer, MD, FACP Guest: Betsy O'Donnell, MD Recent estimates show that only 14 percent of cancers are detected through routine screening, meaning the majority of patients are diagnosed after the onset of clinical symptoms. But multi-cancer early detection (MCED) tests offer the opportunity to potentially expand our ability to detect cancer through a single blood draw. Explore how MCED tests might help bridge the gaps that exist in today’s cancer screening paradigm and the recent studies on these tests with Drs. Tom Beer and Betsy O’Donnell. Dr. Beer is the Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation, and Dr. O’Donnell is the Director of Early Detection and Prevention of Malignant Conditions at the Dana-Farber Cancer Institute.

Host: Neal Shore, MD Between 20 and 50 percent of patients with high-risk localized prostate cancer will develop biochemical resistance, but historically, no Level I evidence for treatment was available. That’s why the EMBARK study is the first phase 3 trial to develop Level I evidence looking at monotherapy T suppression versus monotherapy enzalutamide versus combination enzalutamide and leuprolide. Dive into the findings with Dr. Neal Shore, who presented the “Outcomes of Men with High-Risk Biochemically Recurrent Prostate Cancer Who Suspended Enzalutamide Monotherapy Treatment in the Phase 3 EMBARK Study” session at the 2024 ASCO Genitourinary Cancers Symposium.

Guest: Jessica E. Hawley M.D. M.S. The National Comprehensive Cancer Network (NCCN) has recommended new guidelines for the treatment of prostate Cancer. In this episode, you’ll learn about the top three biggest changes to the NCCN guidelines. Tune in with Dr. Jessica Hawley, Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine, who will also present this topic at the ASCO GU Symposium 2024.

Host: Daniel Kwon, MD Between patient anxiety and insurance implications, there are several challenges associated with delivering germline testing to veterans with advanced prostate cancer. Learn more about these challenges and proposed solutions with Dr. Daniel Kwon, who presented the “Challenges in Patient-Centered Germline Testing Delivery for Veterans with Advanced Prostate Cancer” session at the 2024 ASCO Genitourinary Cancers Symposium.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ravi Rajaram, MD, MSC NEOSTAR is a phase 2 trial with multiple arms looking at different combination therapies in the setting of resectable lung cancer. So what results were found from this study? Join in as Dr. Charles Turck discusses this further with Dr. Ravi Rajaram, Assistant Professor and the Clinical Medical Director in the Thoracic Center in the Department of Thoracic and Cardiovascular Surgery, Division of Surgery, at the University of Texas MD Anderson Cancer Center in Houston.